Table 2.
Comparison of the complete blood count parameters and selected ratios between individual groups (i.e., ASD, ADHD, and control groups) with respect to sex.
| Parameter |
p-Value/ Cohen’s d a vs. d |
p-Value/ Cohen’s d a vs. g |
p-Value/ Cohen’s d d vs. g |
p-Value/ Cohen’s d b vs. e |
p-Value/ Cohen’s d b vs. h |
p-Value/ Cohen’s d e vs. h |
p-Value/ Cohen’s d c vs. f |
p-Value/ Cohen’s d c vs. i |
p-Value/ Cohen’s d f vs. i |
p-Value/ Cohen’s d b vs. c |
p-Value/ Cohen’s d e vs. f |
p-Value/ Cohen’s d h vs. i |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WBC (109/L) | 0.042/0.812 | 0.099/0.700 | 0.999/−0.112 | 0.999/0.332 | 0.999/0.585 | 0.999/0.253 | 0.175/0.971 | 0.818/0.731 | 0.999/−0.241 | 0.999/−0.027 | 0.999/−0.667 | 0.999/−0.174 |
| Neu (109/L) | 0.104/0.694 | 0.082/0.737 | 0.999/0.042 | 0.999/0.012 | 0.999/−0.186 | 0.999/−0.198 | 0.231/0.931 | 0.126/1.019 | 0.999/0.087 | 0.999/0.466 | 0.999/−0.454 | 0.999/−0.740 |
| Lym (109/L) | 0.785/0.321 | 0.793/0.393 | 0.998/0.071 | 0.861/0.536 | 0.621/1.076 | 0.936/0.540 | 0.999/0.245 | 0.999/0.159 | 0.994/−0.086 | 0.444/−0.485 | 0.999/−0.194 | 0.987/0.432 |
| Mon (109/L) | 0.047/0.790 | 0.482/0.557 | 0.694/−0.233 | 0.998/−0.172 | 0.608/−0.737 | 0.960/−0.565 | 0.033/1.184 | 0.235/1.035 | 0.998/−0.149 | 0.429/0.625 | 0.895/−0.731 | 0.206/−1.146 |
| PLT (109/L) | 0.180/0.741 | 0.064/0.556 | 0.999/−0.185 | 0.901/0.831 | 0.999/−0.160 | 0.991/−0.990 | 0.614/0.752 | 0.201/0.789 | 0.998/0.037 | 0.997/0.352 | 0.987/0.431 | 0.942/−0.597 |
| MPV (fL) |
0.999/−0.290 | 0.999/0.075 | 0.780/0.365 | 0.526/−1.368 | 0.999/0.000 | 0.526/1.368 | 0.999/0.082 | 0.999/0.102 | 0.999/0.021 | 0.999/0.120 | 0.293/−1.255 | 0.999/0.093 |
| PDW (%) |
0.319/0.540 | 0.015/0.938 | 0.678/0.398 | 0.999/0.268 | 0.999/0.589 | 0.999/0.321 | 0.999/0.624 | 0.118/1.029 | 0.999/0.405 | 0.999/0.182 | 0.999/−0.175 | 0.999/−0.259 |
| NLR | 0.416/0.275 | 0.600/0.446 | 0.995/0.171 | 0.936/−0.412 | 0.825/−1.017 | 0.825/−0.605 | 0.364/0.519 | 0.268/0.908 | 0.988/0.389 | 0.589/0.713 | 0.987/−0.218 | 0.462/−1.212 |
| PLR | 0.420/0.123 | 0.996/0.283 | 0.954/0.160 | 0.976/−0.348 | 0.352/−1.071 | 0.903/−0.723 | 0.229/0.296 | 0.758/0.747 | 0.999/0.451 | 0.083/0.736 | 0.999/0.093 | 0.589/−1.082 |
| LMR | 0.591/−0.333 | 0.979/−0.109 | 0.779/0.224 | 0.753/0.607 | 0.241/1.756 | 0.621/1.149 | 0.441/−0.705 | 0.445/−0.761 | 0.999/−0.055 | 0.154/−1.062 | 0.962/0.251 | 0.226/1.455 |
| MLR | 0.591/0.349 | 0.979/0.289 | 0.779/−0.060 | 0.753/−0.689 | 0.241/−1.297 | 0.621/−0.608 | 0.441/0.748 | 0.445/0.857 | 0.999/0.110 | 0.154/0.953 | 0.962/−0.483 | 0.226/−1.201 |
| PMR | 0.519/−0.241 | 0.989/−0.059 | 0.670/0.181 | 0.999/0.167 | 0.936/0.476 | 0.976/0.309 | 0.840/−0.358 | 0.970/−0.242 | 0.982/0.116 | 0.977/−0.339 | 0.999/0.186 | 0.977/0.379 |
| MPVLR | 0.763/−0.243 | 0.851/−0.067 | 0.877/0.176 | 0.999/0.029 | 0.621/1.206 | 0.903/1.176 | 0.902/−0.350 | 0.708/−0.495 | 0.999/−0.144 | 0.848/−0.433 | 0.999/−0.053 | 0.943/1.267 |
| MPVPR | 0.999/0.120 | 0.229/0.674 | 0.143/0.554 | 0.999/−0.374 | 0.684/0.394 | 0.276/0.768 | 0.999/−0.526 | 0.958/−1.105 | 0.943/−0.579 | 0.994/−0.899 | 0.916/−0.746 | 0.727/0.601 |
ASD—autism spectrum disorder; ADHD—attention deficit/hyperactivity disorder; WBC—white blood cells; Neu—neutrophils; Lym—lymphocytes; Mon—monocytes; PLT—platelets; MPV—mean platelet volume; PDW—platelet distribution width; NLR—neutrophils to lymphocytes ratio; PLR—platelets to lymphocytes ratio; LMR—lymphocytes to monocytes ratio; MLR—monocytes to lymphocytes ratio; PMR—platelets to monocytes ratio; MPVLR—MPV to lymphocytes ratio; MPVPR—MPV to platelets ratio. A value of p ≤ 0.05 (in bold) was considered statistically significant. a indicates the control group; b indicates the control females; c indicates the control males; d indicates the ASD group; e indicates the ASD females; f indicates the ASD males; g indicates the ADHD group; h indicates the ADHD females; i indicates the ADHD males.